Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,070
  • Shares Outstanding, K 106,861
  • Annual Sales, $ 33,030 K
  • Annual Income, $ -44,630 K
  • EBIT $ -44 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.22
  • Price/Sales 2.19
  • Price/Cash Flow N/A
  • Price/Book 0.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings $-0.06 on 03/24/26
  • Next Earnings Date 05/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 337.18% (+53.67%)
  • Historical Volatility 64.37%
  • IV Percentile 70%
  • IV Rank 23.56%
  • IV High 1,269.33% on 05/08/25
  • IV Low 49.94% on 07/22/25
  • Expected Move (DTE 16) 0.9775 (131.37%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 31
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 1,588
  • Open Int (30-Day) 1,524
  • Expected Range 0.0000 to 1.7216

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.11
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6593 +12.86%
on 03/30/26
0.8750 -14.96%
on 03/05/26
-0.0672 (-8.28%)
since 02/27/26
3-Month
0.6434 +15.65%
on 02/17/26
1.5900 -53.20%
on 01/05/26
-0.8059 (-51.99%)
since 12/31/25
52-Week
0.6434 +15.65%
on 02/17/26
2.9550 -74.82%
on 04/28/25
-1.9659 (-72.54%)
since 04/01/25

Most Recent Stories

More News
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Announces Planned CFO Transition in 2026

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)

Business Summary

MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.

See More

Key Turning Points

3rd Resistance Point 0.8464
2nd Resistance Point 0.8042
1st Resistance Point 0.7741
Last Price 0.7441
1st Support Level 0.7018
2nd Support Level 0.6596
3rd Support Level 0.6295

See More

52-Week High 2.9550
Fibonacci 61.8% 2.0720
Fibonacci 50% 1.7992
Fibonacci 38.2% 1.5264
Last Price 0.7441
52-Week Low 0.6434

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.